The primary objectives of administering a gonadotropin-releasing hormone (GnRH) analog to patients with CPP are to increase adult height and postpone the development of secondary sexual characteristics until a later age that is more compatible with peer norms. This evidence concerns the gene GNRH1 and central precocious puberty.